Palavra-chave: MULTIPLE MYELOMA

{18F}FDG PET/CT P53 METHIONINE METABOLIZING ENZYMES METABOLIC ANGIOGENESIS MONOCLONAL GAMMOPATHY CD56 POLYMORPHISM GRANULOCYTE-COLONY ESSENTIAL THROMBOCYTEMIA 68GA}GA-PSMA-11 NON-HIV-ASSOCIATED LDE PLASMA PREKALLIKREIN METHIONINE SYNTASE REDUCTASE (MTRR) GENE SERIAL ANALYSIS OF GENE EXPRESSION DELETION ANALYSIS OF GENE EXPRESSION AUTOLOGOUS BONE MARROW TRANSPLANTATION 13Q DELETION P53 DELETION SUSCEPTIBILITY PLASMA CELLS STEM CELL TRANSPLANTATION TRANSPLANT-ELIGIBLE P53 GENE COAGULATION OLIGLOCONAL BANDS PLASMATIC PREKALLIKREIN VASCULAR HEMATOPOIETIC PROGENITOR CELLS RISK FACTOR FOLATE AND METHIONINE P53 MUTATION IMAGING TECHNIQUES IN DIAGNOSIS AND MONITORING IMWG THALIDOMIDE NUCLEAR CHROMATIN POLYMORPHISMS VEGF ABNORMAL PROTEIN BAND OLIGOCLONAL CHROMATIN CRYPTOCOCCAL MENINGOENCEPHALITIS INTERNATIONAL MYELOMA WORKING GROUP GENE EXPRESSION PROFILES THALIDOMIDE-CONTAINING ENDOSTATIN GSTM1 PET MTHFR C677T VEGFR2 MGUS DEXAMETHASONE IMIDS GLUTATHIONE S-TRANSFERASE MOLECULAR BIOLOGY PSMA-177LU AUTOLOGOUS TRANSPLANT CHEMOTHERAPY THALIDOMIDE+DEXAMETHASONE MTRR GENE THROMBOCYTEMIA 18F-FDG PET/CT BORTEZOMIB AUTOLOGOUS STEM CELL TRANSPLANTATION METHIONINE SYNTASE REDUCTASE CLINICAL TRIAL MTHFR GENE F-FDG PET/CT LIPOSOMAL DAUNORUBICIN SINGLE AUTOLOGOUS HOMOZYGOUS 66GG GSTT1 PROGNOSIS SAGE ORAL AMYLOIDOSIS LEUKEMIA MTRR TREATMENT PROGNOSTIC FACTORS MTR GENE GENE EXPRESSION PROFILE ORAL CAVITY CHROMATIN FRACTAL CD34+ TYMS GENE PROGRESSION-FREE SURVIVAL FIBRINOLYSIS DD PROTOCOL CODON 72 AUTOLOGOUS RISK PROGRESSION